Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alert Triggered for MFIC Corp.
MFIC Reached a New 52 Week High at $1.72
MFIC rose 4.2% to a new 52 week high of $1.72. During the last 52 weeks, MFIC's price has ranged from $1.10 on August 10, 2006 to today's high of $1.72.
Good choice. Welcome Stock H.O.G.
Advanced Viral Research Files an Amendment to its Existing IND to Include Topical and Intralesional Therapy
YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that it has filed an amendment with the FDA to its existing IND to expand the use of its product, AVR118 to include topical and intralesional therapy. These applications could potentially be used to treat a wide variety of common dermatologic conditions that are extremely problematic to treat.
“Having successfully completed a preliminary wound healing study at the University of Miami, as well as completing a phase I study confirming safety, we are ready to begin a phase II pilot study in patients with common skin problems. Based on recent discussions with clinical investigators, we are anxious to finalize our plans for studying how AVR118’s ability to promote tissue repair and regeneration can be put to use in the clinical setting,” says Stephen Elliston, CEO of Advanced Viral.
“The current plan is to treat skin lesions ranging from surgical wounds to acne scars. If efficacy can be established as a topical or intralesional therapy, the commercial prospects for our product will increase dramatically. We have begun work in developing a topical formulation that can easily be applied directly onto the skin.
The multi-billion dollar wound healing industry is in great need of products that can not only facilitate the healing of wounds, but also minimize the cosmetic impact of scarring. Dermatologists we have been in discussions with are extremely comfortable in the safety profile and are anxious to explore its efficacy in a wide variety of skin lesions,” added Elliston.
Advanced Viral Research Corp is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the systematic control of symptoms associated with cancer and other serious diseases. ADVR's lead product, AVR118 represents a new class of complex cytoprotective agents that target among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models.
Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV/AIDS and chronic inflammation are potential disease targets for AVR118 therapy.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.
SOURCE: Advanced Viral Research Corp.
Yep, just got some at .095
Advanced Viral Research Files an Amendment to its Existing IND to Include Topical and Intralesional Therapy
YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that it has filed an amendment with the FDA to its existing IND to expand the use of its product, AVR118 to include topical and intralesional therapy. These applications could potentially be used to treat a wide variety of common dermatologic conditions that are extremely problematic to treat.
“Having successfully completed a preliminary wound healing study at the University of Miami, as well as completing a phase I study confirming safety, we are ready to begin a phase II pilot study in patients with common skin problems. Based on recent discussions with clinical investigators, we are anxious to finalize our plans for studying how AVR118’s ability to promote tissue repair and regeneration can be put to use in the clinical setting,” says Stephen Elliston, CEO of Advanced Viral.
“The current plan is to treat skin lesions ranging from surgical wounds to acne scars. If efficacy can be established as a topical or intralesional therapy, the commercial prospects for our product will increase dramatically. We have begun work in developing a topical formulation that can easily be applied directly onto the skin.
The multi-billion dollar wound healing industry is in great need of products that can not only facilitate the healing of wounds, but also minimize the cosmetic impact of scarring. Dermatologists we have been in discussions with are extremely comfortable in the safety profile and are anxious to explore its efficacy in a wide variety of skin lesions,” added Elliston.
Advanced Viral Research Corp is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the systematic control of symptoms associated with cancer and other serious diseases. ADVR's lead product, AVR118 represents a new class of complex cytoprotective agents that target among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models.
Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV/AIDS and chronic inflammation are potential disease targets for AVR118 therapy.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.
SOURCE: Advanced Viral Research Corp.
Advanced Viral Research Files an Amendment to its Existing IND to Include Topical and Intralesional Therapy
YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that it has filed an amendment with the FDA to its existing IND to expand the use of its product, AVR118 to include topical and intralesional therapy. These applications could potentially be used to treat a wide variety of common dermatologic conditions that are extremely problematic to treat.
“Having successfully completed a preliminary wound healing study at the University of Miami, as well as completing a phase I study confirming safety, we are ready to begin a phase II pilot study in patients with common skin problems. Based on recent discussions with clinical investigators, we are anxious to finalize our plans for studying how AVR118’s ability to promote tissue repair and regeneration can be put to use in the clinical setting,” says Stephen Elliston, CEO of Advanced Viral.
“The current plan is to treat skin lesions ranging from surgical wounds to acne scars. If efficacy can be established as a topical or intralesional therapy, the commercial prospects for our product will increase dramatically. We have begun work in developing a topical formulation that can easily be applied directly onto the skin.
The multi-billion dollar wound healing industry is in great need of products that can not only facilitate the healing of wounds, but also minimize the cosmetic impact of scarring. Dermatologists we have been in discussions with are extremely comfortable in the safety profile and are anxious to explore its efficacy in a wide variety of skin lesions,” added Elliston.
Advanced Viral Research Corp is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the systematic control of symptoms associated with cancer and other serious diseases. ADVR's lead product, AVR118 represents a new class of complex cytoprotective agents that target among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models.
Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV/AIDS and chronic inflammation are potential disease targets for AVR118 therapy.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.
SOURCE: Advanced Viral Research Corp.
Rant about this: Equifax Credit Marketing is selling your credit information without your permission! If you apply for a mortgage and your bank, etc checks credit through them this is a signal for Equifax to "shop" your info to other likely lenders.
If you are concerned just call Mr. Paul Vasquez at 630-495-5016 and let him have an earful.
Webcast Alert: CEL-SCI Corp. Announces Its Informed Investors Forum Webcast
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corp. (AMEX: CVM) announces the following Webcast:
What: CEL-SCI Corp. Informed Investors Forum Webcast
When: November 14, 2006 @ 11:00 AM Eastern
Where: http://www.investorcalendar.com/EventPage.asp?ID=111447
How: Live over the Internet -- Simply log on to the web at the address above.
Contact: Gavin de Windt, 703-506-9460 or gdewindt@cel-sci.com
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=111447 or http://www.investorcalendar.com/
CEL-SCI Corporation is a pioneer in biotechnology research. We develop novel drugs for the treatment of cancer and infectious diseases. Our lead product, Multikine®, is designed to improve first line therapy for the treatment of head & neck cancer. The concept behind Multikine is to harness the power of the immune system against cancer. Multikine is a biologic comprised of cytokines that stimulate the human immune system to overcome tumor tolerance.
CEL-SCI recently announced that Multikine demonstrated a 33–40% increase in the median survival at 3 ½ years post-surgery in head & neck cancer patients when administered as a local injection, outpatient, prior to standard first-line therapy, in Phase II trials. Local/regional control also improved. The patients were all diagnosed with advanced untreated primary tumors.
Multikine is cleared in Canada for a Phase III clinical trial designed to improve first line therapy for advanced primary head & neck cancer. The endpoints of the study are survival and local regional control.
Head & neck cancer accounts for 5% of all cancers worldwide, with 500,000 new cases each year worldwide. The potential market exceeds $1 billion.
CEL-SCI’s Asian partner, Orient Europharma, will either be running a separate Phase III study with Multikine in head & neck cancer or will share the costs of the Phase III study with CEL-SCI. The Far East has a very large number of head & neck cancer patients.
Another patented CEL-SCI technology called L.E.A.P.S.™, and its lead candidate CEL-1000, have enjoyed significant government funding as well as collaborations with the U.S. Navy, U.S. Army and National Institutes of Health (NIH). CEL-1000 has been shown to protect against viruses and parasitic diseases in animals.
In December 2005, CEL-SCI signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to test CEL-1000 against the avian (bird) flu virus H5N1 in animal models.
CEL-SCI is listed on the AMEX under the stock symbol CVM.
Contacts
CEL-SCI Corp.
Gavin de Windt, 703-506-9460
gdewindt@cel-sci.com
At least this gets NDOL some press:
Bull in Advantage, LLC names PYPR, SDRG, NDOL, WNBD "Red Hot Penny Stock"
Published in M2 PressWIRE on Monday, 13 November 2006 at 15:03 GMT
Copyright (C) 2006, M2 Communications Ltd.
Bull in Advantage, LLC A.K.A Redhotpennystock.com names PayPro, Incorporated (Pink Sheets: PYPR), Silver Dragon Resources Inc. (OTCBB: SDRG), North-West Oil Group (Pink Sheets: NDOL) and Winning Brands Corporation (Pink Sheets: WNBD) its "Red Hot Penny Stock."
Visit our sister site at http://prudentpennyprofit.com/ to see a promotional ad on behalf of Allied Energy Group, Inc.. (Pink Sheets: AGGI)
Visit http://www.redhotpennystock.com/ to sign up for our ahead of the curve newsletter!
PayPro, Incorporated (Pink Sheets: PYPR- http://finance.yahoo.com/q?s=PYPR.PK)
A message from the President of PayPro Latin America Sociedad Anonima, (S.A.), hereinafter "PayPro LATAM," a Panamanian Stock Corporation with a business philosophy that: PROMOTES & ASSISTS THE COMMERCIAL INTEGRATION OF LATIN AMERICA INTO THE ECONOMIC DEVELOPMENT OF THE WESTERN HEMISPHERE, PAN-AMERICA.
"PayPro LATAM" was incorporated in the Republic of Panama, The Hub of the Americas, to coordinate and to carry out its Pan-American business plan. The company is also working with PayPro's Finance division, E-Biz Financial Corporation, www.e-bizfinance.com, to develop programs to offer micro loans, currency exchange and the E-BIZ Wallet, to qualified natural persons and legal entities, throughout the company's operations regions, as follows: AMERICA I The Caribbean AMERICA II United States, Canada, & Mexico AMERICA III Central America & Panama AMERICA IV South America
"PayPro LATAM" is an operating company and beneficiary of Fundacion PayPro, a Panamanian Private Interest Foundation, legally authorized to act as a depository for any type of real or financial assets and PayPro shares, and to hold them in safekeeping on behalf of and for the benefit of its Beneficiaries, PDR's holders which may be legal entities or natural persons of good standing.
PayPro Latin America Sociedad Anonima, (S.A.) is The Caribbean (A-I), Central America & Panama (A-III) & South American (A-IV) partner for PayPro Incorporated (A-II) a U.S. Public Company duly registered in the State of Nevada and PayPro Card Corporation, based in Dallas, Texas, U.S.A., owner of "MyBankCard" a value added debit card global payment system.
Also, PayPro's Travel division will begin soon a promotion for Business & Investment Tourism travel packages identified as: "Come visit Panama... see for yourself..."
The PayPro Team is a dynamic group of companies with a defined forward looking vision for Pan-American economic development through commercial integration in Latin America; from micro to macro perspectives: WHILE PROTECTING our Flora, Fauna and Water resources... PayPro promotes the individual commitment to family carbon neutrality status "SPONSORING MICRO FORESTS." WE DO NOT GIVE ADVISE...
WE ASSISTS TO COORDINATE PAN-AMERICAN DEVELOPMENT PLANS...
About PayPro Incorporated: PayPro Incorporated (PINK SHEETS: PYPR) is a global e-commerce and e-biz Solutions Company offering interactive e-commerce and e-biz programs. PayPro offers a range of goods and services ON LINE as follows: Visa prepaid cards; e-commerce merchant accounts; Life insurance policies, Gold transactions; Telephone services, Text messaging, VoIP, Micro forests properties, Real estate investment participations, Fixed and variable income Real estate properties in Costa Rica and Panama, Offshore financial services, Asset management and protection; Travel services, Leisure, Business, Health, Relocation services, and Digital marketing services.
Silver Dragon Resources Inc. (OTCBB: SDRG - http://finance.yahoo.com/q?s=SDRG.OB)
Silver Dragon Resources Inc. (OTCBB: SDRG) is pleased to announce the completion of the purchase of Sino Silver Corp.'s 60% equity interest in Sanhe Sino-Top Resources and Technologies Ltd. ("Sino-Top") following receipt of the business license from the local industrial and commercial administration in Langfang City, China.
After receiving the Certificate of Approval for the Establishment of Enterprises with Foreign Investment in the People's Republic of China from the Ministry Of Commerce ("MOC") (See press release September 28, 2006), Silver Dragon is now officially recognized by the MOC and the local industrial and commercial administration in Langfang City in China's Hebei province as the majority equity interest owner in Sino-Top.
In accordance with its obligations for the final segment of the closing under the Asset Purchase Agreement with Sino Silver, Silver Dragon paid US$400,000 and released 4,250,000 restricted shares of its common stock from escrow to Sino Silver.
"It is extremely gratifying to deliver on the commitments we made to our long-time shareholders and to our new shareholders when we announced our decision to proceed with the acquisition of these significant assets which will be included in our year-end financial statements," said Marc Hazout, President and CEO of Silver Dragon. "The Erbahuo Silver District is one of the most prolific silver districts in the world and we can now begin to pursue the monetization of these assets which are comprised of the exploration and mining rights in over 240 square kilometers of property which includes the operating Erbahuo silver mine." About Silver Dragon Resources, Inc.
Silver Dragon Resources Inc. is a mining and metal company focused on the exploration, acquisition, development and operation of silver mines in proven silver districts globally. Silver Dragon's objective is to acquire silver mining assets that contain promising exploration targets, have highly leveraged, out-of-the-money silver deposits, and/or are producing properties with significant untapped exploration potential. It is management's objective to grow Silver Dragon into a significant silver producer by developing the Cerro las Minitas and the Erbahuo projects in Mexico and China, respectively. For more information, please visit the Company's website at: www.silverdragonresources.com (now available in Chinese).
North-West Oil Group (PINKSHEETS: NDOL - http://finance.yahoo.com/q?s=NDOL.PK)
(PINKSHEETS: NDOL) -- North-West Oil Group (formerly Nord Oil International) recently announced that it is currently conducting negotiations in order to build 10 new gas stations in the Northwest Region of Russia. The project also encompasses additional services such as car washes and the construction of small hotels next to the gas stations.
The Northwest Region of Russia includes the Republics of Karelia and Komi, Nenets Autonomous Area, Arkhangelsk, Vologda, Kaliningrad, Kirov, Leningrad, Murmansk, Novgorod and Pskov Regions and St. Petersburg.
Northwest Russia, with a population of roughly 14.3 million people, has attracted a high percentage of total direct foreign investment in Russia, and has distinguished itself by the progressive outlook of many of its political/economic leaders. Among foreign investors of Northwest Russia are major multinational companies, such as: General Electric, ABB, Siemens, JT-International, Philip Morris, Wrigley, Nestle, Coca-Cola and Pepsi-Cola, Conoco, Caterpillar, Procter and Gamble, ICN Pharmaceuticals, De Biers, etc. Investment projects range from Conoco's $400 million investment in the Polar Lights oil field in Naryan'mar, Arkangelsk Region, to Ford Motor Company's $150 million production facility in the Leningrad Region.
Ernest Malyshev, President of North-West Oil Group, stated, "We are very pleased with the way these negotiations are going. It is an important step for our company in order to diversify its business strategy. These gas stations are absolutely necessary to support the growing business infrastructure of the region. The high profits generated shall provide a steady additional source of cash for the Company." About Nord Oil / North-West Oil Group North-West Oil Group (formerly Nord Oil International) is a reporting, publicly traded Oil & Gas company trading under the ticker symbol NDOL on the US Pink Sheets market as well as on the Frankfurt Exchange under symbol CXIA. Nord Oil International and the North-West Oil Group merged on May 11, 2006. The company presently produces over 120,000 Metric Tons of crude oil yearly.
For whatever this is worth, at least it gets our name out there:
Bull in Advantage, LLC names PYPR, SDRG, NDOL, WNBD "Red Hot Penny Stock"
Published in M2 PressWIRE on Monday, 13 November 2006 at 15:03 GMT
Copyright (C) 2006, M2 Communications Ltd.
Bull in Advantage, LLC A.K.A Redhotpennystock.com names PayPro, Incorporated (Pink Sheets: PYPR), Silver Dragon Resources Inc. (OTCBB: SDRG), North-West Oil Group (Pink Sheets: NDOL) and Winning Brands Corporation (Pink Sheets: WNBD) its "Red Hot Penny Stock."
Visit our sister site at http://prudentpennyprofit.com/ to see a promotional ad on behalf of Allied Energy Group, Inc.. (Pink Sheets: AGGI)
Visit http://www.redhotpennystock.com/ to sign up for our ahead of the curve newsletter!
PayPro, Incorporated (Pink Sheets: PYPR- http://finance.yahoo.com/q?s=PYPR.PK)
A message from the President of PayPro Latin America Sociedad Anonima, (S.A.), hereinafter "PayPro LATAM," a Panamanian Stock Corporation with a business philosophy that: PROMOTES & ASSISTS THE COMMERCIAL INTEGRATION OF LATIN AMERICA INTO THE ECONOMIC DEVELOPMENT OF THE WESTERN HEMISPHERE, PAN-AMERICA.
"PayPro LATAM" was incorporated in the Republic of Panama, The Hub of the Americas, to coordinate and to carry out its Pan-American business plan. The company is also working with PayPro's Finance division, E-Biz Financial Corporation, www.e-bizfinance.com, to develop programs to offer micro loans, currency exchange and the E-BIZ Wallet, to qualified natural persons and legal entities, throughout the company's operations regions, as follows: AMERICA I The Caribbean AMERICA II United States, Canada, & Mexico AMERICA III Central America & Panama AMERICA IV South America
"PayPro LATAM" is an operating company and beneficiary of Fundacion PayPro, a Panamanian Private Interest Foundation, legally authorized to act as a depository for any type of real or financial assets and PayPro shares, and to hold them in safekeeping on behalf of and for the benefit of its Beneficiaries, PDR's holders which may be legal entities or natural persons of good standing.
PayPro Latin America Sociedad Anonima, (S.A.) is The Caribbean (A-I), Central America & Panama (A-III) & South American (A-IV) partner for PayPro Incorporated (A-II) a U.S. Public Company duly registered in the State of Nevada and PayPro Card Corporation, based in Dallas, Texas, U.S.A., owner of "MyBankCard" a value added debit card global payment system.
Also, PayPro's Travel division will begin soon a promotion for Business & Investment Tourism travel packages identified as: "Come visit Panama... see for yourself..."
The PayPro Team is a dynamic group of companies with a defined forward looking vision for Pan-American economic development through commercial integration in Latin America; from micro to macro perspectives: WHILE PROTECTING our Flora, Fauna and Water resources... PayPro promotes the individual commitment to family carbon neutrality status "SPONSORING MICRO FORESTS." WE DO NOT GIVE ADVISE...
WE ASSISTS TO COORDINATE PAN-AMERICAN DEVELOPMENT PLANS...
About PayPro Incorporated: PayPro Incorporated (PINK SHEETS: PYPR) is a global e-commerce and e-biz Solutions Company offering interactive e-commerce and e-biz programs. PayPro offers a range of goods and services ON LINE as follows: Visa prepaid cards; e-commerce merchant accounts; Life insurance policies, Gold transactions; Telephone services, Text messaging, VoIP, Micro forests properties, Real estate investment participations, Fixed and variable income Real estate properties in Costa Rica and Panama, Offshore financial services, Asset management and protection; Travel services, Leisure, Business, Health, Relocation services, and Digital marketing services.
Silver Dragon Resources Inc. (OTCBB: SDRG - http://finance.yahoo.com/q?s=SDRG.OB)
Silver Dragon Resources Inc. (OTCBB: SDRG) is pleased to announce the completion of the purchase of Sino Silver Corp.'s 60% equity interest in Sanhe Sino-Top Resources and Technologies Ltd. ("Sino-Top") following receipt of the business license from the local industrial and commercial administration in Langfang City, China.
After receiving the Certificate of Approval for the Establishment of Enterprises with Foreign Investment in the People's Republic of China from the Ministry Of Commerce ("MOC") (See press release September 28, 2006), Silver Dragon is now officially recognized by the MOC and the local industrial and commercial administration in Langfang City in China's Hebei province as the majority equity interest owner in Sino-Top.
In accordance with its obligations for the final segment of the closing under the Asset Purchase Agreement with Sino Silver, Silver Dragon paid US$400,000 and released 4,250,000 restricted shares of its common stock from escrow to Sino Silver.
"It is extremely gratifying to deliver on the commitments we made to our long-time shareholders and to our new shareholders when we announced our decision to proceed with the acquisition of these significant assets which will be included in our year-end financial statements," said Marc Hazout, President and CEO of Silver Dragon. "The Erbahuo Silver District is one of the most prolific silver districts in the world and we can now begin to pursue the monetization of these assets which are comprised of the exploration and mining rights in over 240 square kilometers of property which includes the operating Erbahuo silver mine." About Silver Dragon Resources, Inc.
Silver Dragon Resources Inc. is a mining and metal company focused on the exploration, acquisition, development and operation of silver mines in proven silver districts globally. Silver Dragon's objective is to acquire silver mining assets that contain promising exploration targets, have highly leveraged, out-of-the-money silver deposits, and/or are producing properties with significant untapped exploration potential. It is management's objective to grow Silver Dragon into a significant silver producer by developing the Cerro las Minitas and the Erbahuo projects in Mexico and China, respectively. For more information, please visit the Company's website at: www.silverdragonresources.com (now available in Chinese).
North-West Oil Group (PINKSHEETS: NDOL - http://finance.yahoo.com/q?s=NDOL.PK)
(PINKSHEETS: NDOL) -- North-West Oil Group (formerly Nord Oil International) recently announced that it is currently conducting negotiations in order to build 10 new gas stations in the Northwest Region of Russia. The project also encompasses additional services such as car washes and the construction of small hotels next to the gas stations.
The Northwest Region of Russia includes the Republics of Karelia and Komi, Nenets Autonomous Area, Arkhangelsk, Vologda, Kaliningrad, Kirov, Leningrad, Murmansk, Novgorod and Pskov Regions and St. Petersburg.
Northwest Russia, with a population of roughly 14.3 million people, has attracted a high percentage of total direct foreign investment in Russia, and has distinguished itself by the progressive outlook of many of its political/economic leaders. Among foreign investors of Northwest Russia are major multinational companies, such as: General Electric, ABB, Siemens, JT-International, Philip Morris, Wrigley, Nestle, Coca-Cola and Pepsi-Cola, Conoco, Caterpillar, Procter and Gamble, ICN Pharmaceuticals, De Biers, etc. Investment projects range from Conoco's $400 million investment in the Polar Lights oil field in Naryan'mar, Arkangelsk Region, to Ford Motor Company's $150 million production facility in the Leningrad Region.
Ernest Malyshev, President of North-West Oil Group, stated, "We are very pleased with the way these negotiations are going. It is an important step for our company in order to diversify its business strategy. These gas stations are absolutely necessary to support the growing business infrastructure of the region. The high profits generated shall provide a steady additional source of cash for the Company." About Nord Oil / North-West Oil Group North-West Oil Group (formerly Nord Oil International) is a reporting, publicly traded Oil & Gas company trading under the ticker symbol NDOL on the US Pink Sheets market as well as on the Frankfurt Exchange under symbol CXIA. Nord Oil International and the North-West Oil Group merged on May 11, 2006. The company presently produces over 120,000 Metric Tons of crude oil yearly.
midas-I have been reading message boards for years and one thing is for certain, there are many fools on both sides. There is the fool who sees everything about the company as 100% positive just because he bought and the fool who sees 100% negative because he is out or has an agenda. In the end both types are fools.
Thanks for your honest DD both negative and positive.
CEL-SCI CEO to Present at the Life Science Informed Investor Forum
9:00a ET November 10, 2006 (PR NewsWire) CEL-SCI CORPORATION (Amex: CVM), a drug development company with its lead cancer product cleared for a Phase III trial in Canada, announced that its Chief Executive Officer, Geert Kersten, is a featured presenter at the Life Science Informed Investors On-line Forum. The webcast presentation is scheduled for Tuesday, November 14, 2006 at 11:00 a.m. (Eastern Daylight Time) and can be accessed via the Internet at http://www.informedinvestors.com.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine(R) is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI's other products, which are currently in pre- clinical stage and are funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
SOURCE CEL-SCI Corporation
Pinnacle Digest: Pinnacle's Review of CEL-SCI Corp.
4:56a ET November 8, 2006 (Comtex) CEL-SCI Corp (AMEX:CVM) is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. Its lead product is Multikine and is being developed for the treatment of cancer. The main focus of Multikine is to harness the power of the immune system and stimulate it to fight cancer. Multikine is a biologic compromised of cytokines that stimulate the human immune system to overcome tumor tolerance. PinnacleDigest feels this could prove to be a major development for CEL-SCI Corp. Visit www.pinnacledigest.com to read more about this company and to learn why our client base continues to grow.
In Biotech news Watson Pharmaceuticals Inc., a generic drug maker, which made headlines last week after buying Andrx Corp. for 1.9 billion has reported losses in the third quarter. Prices for its copied brand name medicines are falling, and its third quarter results reflected that showing losses of 12 percent.
Their profit margin for these generic drugs has fallen 32 percent from a 41 percent the previous year. This is going to be a continued trend, unless they stay the cheapest and keep their expenses down. It is very easy to duplicate these drugs and many companies are taking that approach. Watson Pharmaceuticals Inc. should be even more concerned as they derive roughly 75% of their revenue from generic birth-control pills, painkillers and other drugs. Companies in this industry have their work cut out for them, to stay a step ahead as the generic drug revolution continues.
Let's look back at CEL-SCI and the aspects of their product Multikine. It is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines and colony-stimulating factors, currently being developed for treatment of cancer. It has been demonstrated to be safe and non-toxic. What an amazing feeling it must be to provide a drug that helps people sustain life and recover. The advancements of this drug could prove pivotal in the success of CEL-SCI. To read more visit us at www.pinnacledigest.com.
To continue with this report as well as other related articles, please visit www.pinnacledigest.com for a complimentary membership. It should be stated that our membership requires no credit card information, nor any commitment to our service. If you would like to contact us please write to support@pinnacledigest.com.
PinnacleDigest has no vested interest in the company mentioned herein. This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles such as this, and many other services we know you will find valuable. Keeping you informed and up-to-date with the market is one of our main goals. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.
About Pinnacle Digest
Pinnacledigest.com is an emerging online financial newsletter community. We put together informative material, capturing the information that we know will give you an edge to your portfolio and more specifically your investment approach.
Once a member of PinnacleDigest you will be able to access our complimentary full-length research reports on selected companies, our weekly volumes, and our market overviews. In addition to these services we are confident you will enjoy our many other services, which are also available to all our members.
We pride ourselves in having a multi purpose online magazine and encourage you to join our community.
This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.
All material herein was prepared by Pinnacledigest.com (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by Pinnacledigest.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Pinnacledigest.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Pinnacledigest.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Pinnacledigest.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
"nanopatent, Matt and Bob already warned you about killing posts just because you disagree with them. Don't be surprised if you "become absent" from this board for a while..."
and miccrocrap, dont be surprised when you go missing also--after the SEC and other law enforcement types take care of you! Just as soon as I find the articles I will post them, to show SEC has acted on internet posters attempting stock manipulation.
.
CombiMatrix Molecular Diagnostics Announces the Launch
of Powerful New Melanoma Test
Nov 10 2006, 5:00 AM EST
BIOWIRE
Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that
its CombiMatrix group's subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX)
has launched a new test that discriminates malignant melanoma from benign moles.
The test, based on CombiMatrix Corporation's CustomArray(R) platform,
is a powerful new molecular diagnostic tool
that enables pathologists to resolve difficult-to-diagnose cases
through an objective genetic analysis.
This test will be introduced to the melanoma community
at the 10th Anniversary Benefit of the William S. Graham Foundation
for Melanoma Research, Inc. being held in San Francisco on November 11, 2006.
CombiMatrix is the corporate sponsor for this event and
a corporate sponsor for the organization.
More information is available at http://www.bfmelanoma.com/gala06.html.
"This exciting new test represents a breakthrough in the field of dermatology,"
said Dr. Scott Binder, M.D.,
Professor of Clinical Pathology and Dermatology, Chief of Dermatopathology,
and Senior Vice Chairman at the David Geffen School of Medicine at UCLA.
"As a dermatopathologist I am often called upon to make very difficult decisions
regarding whether or not a patient has malignant melanoma,
particularly after traditional laboratory methods have failed
to provide a clear diagnosis.
This test from CombiMatrix Molecular Diagnostics provides me
with a powerful new tool to help resolve many of these tough cases."
"Melanoma is the fastest growing cancer in the United States,
and like most cancers early identification and detection
is an important factor in survival. We are encouraged that this new test
is now available to physicians and patients in our battle against
this often fatal disease," said Karen Graham, the Founder and Chairperson
of the William S. Graham Foundation for Melanoma Research.
"I founded the William S. Graham Foundation in honor of my son, Billy,
who died as a result of the mis-diagnosis of melanoma.
Had this test been available then, the outcome might have been different."
"We are very excited about the release of this powerful new diagnostic service,"
said Matt Watson, CEO of CombiMatrix Molecular Diagnostics.
"This is the second microarray service that we have launched
in as many calendar quarters, and it is only the first
in a broad menu of array-based cancer tests
that we hope to release in the near future."
"We have now launched a test based on our
Bacterial Artificial Chromosome Platform
(see http://www.combimatrix.com/pr/090506.pdf )
and a test based on our CustomArray-brand
oligomer-based microarray platform," stated Dr. Amit Kumar,
President and CEO of CombiMatrix and Chairman of CombiMatrix Molecular Diagnostics.
"To our knowledge, we are the only company that has both of these capabilities."
http://www.genengnews.com/news/bnitem.aspx?name=8565693
====
CombiMatrix Molecular Diagnostics Announces the Launch
of Powerful New Melanoma Test
Nov 10 2006, 5:00 AM EST
BIOWIRE
Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that
its CombiMatrix group's subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX)
has launched a new test that discriminates malignant melanoma from benign moles.
The test, based on CombiMatrix Corporation's CustomArray(R) platform,
is a powerful new molecular diagnostic tool
that enables pathologists to resolve difficult-to-diagnose cases
through an objective genetic analysis.
This test will be introduced to the melanoma community
at the 10th Anniversary Benefit of the William S. Graham Foundation
for Melanoma Research, Inc. being held in San Francisco on November 11, 2006.
CombiMatrix is the corporate sponsor for this event and
a corporate sponsor for the organization.
More information is available at http://www.bfmelanoma.com/gala06.html.
"This exciting new test represents a breakthrough in the field of dermatology,"
said Dr. Scott Binder, M.D.,
Professor of Clinical Pathology and Dermatology, Chief of Dermatopathology,
and Senior Vice Chairman at the David Geffen School of Medicine at UCLA.
"As a dermatopathologist I am often called upon to make very difficult decisions
regarding whether or not a patient has malignant melanoma,
particularly after traditional laboratory methods have failed
to provide a clear diagnosis.
This test from CombiMatrix Molecular Diagnostics provides me
with a powerful new tool to help resolve many of these tough cases."
"Melanoma is the fastest growing cancer in the United States,
and like most cancers early identification and detection
is an important factor in survival. We are encouraged that this new test
is now available to physicians and patients in our battle against
this often fatal disease," said Karen Graham, the Founder and Chairperson
of the William S. Graham Foundation for Melanoma Research.
"I founded the William S. Graham Foundation in honor of my son, Billy,
who died as a result of the mis-diagnosis of melanoma.
Had this test been available then, the outcome might have been different."
"We are very excited about the release of this powerful new diagnostic service,"
said Matt Watson, CEO of CombiMatrix Molecular Diagnostics.
"This is the second microarray service that we have launched
in as many calendar quarters, and it is only the first
in a broad menu of array-based cancer tests
that we hope to release in the near future."
"We have now launched a test based on our
Bacterial Artificial Chromosome Platform
(see http://www.combimatrix.com/pr/090506.pdf )
and a test based on our CustomArray-brand
oligomer-based microarray platform," stated Dr. Amit Kumar,
President and CEO of CombiMatrix and Chairman of CombiMatrix Molecular Diagnostics.
"To our knowledge, we are the only company that has both of these capabilities."
http://www.genengnews.com/news/bnitem.aspx?name=8565693
====
MFIC Posts Greater Than 23% Increase for Both Third Quarter & Nine Month Revenues
4:55p ET November 8, 2006 (Business Wire) MFIC Corporation (OTCBB: MFIC) today reported revenues for the quarter ended September 30, 2006 of $3.55 million, representing an increase of approximately $670
NEW YORK: Morgan Stanley Inc. was fined $500,000 (€391,359) by the New York Stock Exchange for failure to file accurate short-interest sales reports to several U.S. stock exchanges.
The Big Board said Wednesday the brokerage failed to "establish and maintain appropriate procedures" to disclose its short selling. The inaccurate reports were filed during an "unknown but significant" number of years, according to the NYSE.
The fine will be split between the NYSE, National Association of Securities Dealers, and the American Stock Exchange. The NASD is the regulatory body responsible for the Nasdaq Stock Market.
Morgan Stanley agreed to the fine, and neither admitted or denied wrongdoing. The fine was given to the New York-based financial company through NYSE Regulation Inc.
Short-interest transactions involves the sale of a security at the current price, which is then settled with shares lent to the seller by a third party. The seller hopes to make money off the trade by betting the price of the security will go down.
Brokerages are required to report their short positions on a monthly basis.
Morgan Stanley fell 36 cents to $75.54.
NEW YORK: Morgan Stanley Inc. was fined $500,000 (€391,359) by the New York Stock Exchange for failure to file accurate short-interest sales reports to several U.S. stock exchanges.
The Big Board said Wednesday the brokerage failed to "establish and maintain appropriate procedures" to disclose its short selling. The inaccurate reports were filed during an "unknown but significant" number of years, according to the NYSE.
The fine will be split between the NYSE, National Association of Securities Dealers, and the American Stock Exchange. The NASD is the regulatory body responsible for the Nasdaq Stock Market.
Morgan Stanley agreed to the fine, and neither admitted or denied wrongdoing. The fine was given to the New York-based financial company through NYSE Regulation Inc.
Short-interest transactions involves the sale of a security at the current price, which is then settled with shares lent to the seller by a third party. The seller hopes to make money off the trade by betting the price of the security will go down.
Brokerages are required to report their short positions on a monthly basis.
Morgan Stanley fell 36 cents to $75.54.
BI Research Update Line 11/9/06- Paincare (PRZ) (Speculative Buy)
North-West Oil Group Finalizing Purchase of Oil Terminal in Latvia
2006-11-09 10:07 ET - News Release
NEW YORK, NY -- (MARKET WIRE) -- 11/09/06
North-West Oil Group (PINKSHEETS: NDOL) (FRANKFURT: CXIA) (formerly Nord Oil International Inc.) announced today that it is finalizing the purchase of an oil terminal in the Port of Liepaja in Latvia. The terminal is currently being used for the transfer of oven fuel and vacuum gas oil. The main suppliers of those products are Mozyrsky and Novopolotsky refineries as well as refineries from Russia, Ukraine and Kazakhstan. Work is currently being conducted at the port in order to increase its depth that will be finished in 2007. Tanker traffic is expected to increase substantially after the work is completed. When the decision for purchase is finalized, the transaction will be completed before the end of November 2006.
The Port of Liepaja enjoys the most southwestern location of Latvian ports. Because of its favorable geographic location, the port is one of two ice-free ports in Latvia that makes it a convenient transport link between Eastern and Western Europe even during the severest winters.
The Port of Liepaja is part of the Liepaja Specialized Economic Zone (SEZ). Companies working in Freeports and North-West Oil Group shall receive up to an 80% tax discount.
"This proposed purchase will allow us to increase the return from the sale of our own resources as well as to receive additional income from providing transfer services," said the President of North-West Oil Group, Mr. Ernest Malyshev.
About North-West Oil Group
North-West Oil Group is a reporting, publicly traded Oil & Gas company trading under the ticker symbol NDOL on the US Pink Sheets market as well as on the Frankfurt Exchange under symbol CXIA. Nord Oil International and the North-West Oil Group merged on May 11, 2006. Application has been filed for a new trading symbol. The company presently produces over 120,000 Metric Tons of crude oil yearly.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
Contact:
Ken Maciora
Investor Relations
516-750-9719
Press@empirerelations.com
MFIC Posts Greater Than 23% Increase for Both Third Quarter & Nine Month Revenues
Wednesday November 8, 4:55 pm ET
NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (OTCBB: MFIC - News) today reported revenues for the quarter ended September 30, 2006 of $3.55 million, representing an increase of approximately $670,000, or 23.3%, compared with revenues of $2.88 million for the quarter ended September 30, 2005.
For the quarter ended September 30, 2006, the Company posted net income of approximately $85,000, or $.01 per diluted share, as compared with a net loss of approximately $297,000, or $0.03 per diluted share, for the quarter ended September 30, 2005. The third quarter 2006 included an income tax provision of $57,000 while the third quarter of 2005 had no income tax benefit or provision.
For the nine month period ended September 30, 2006, revenues increased $2,033,000, or 23.7%, to approximately $10.6 million, and the Company reported a net profit of $0.02 per diluted share, as compared with approximately $8.6 million in revenues, and a net loss of $0.05 per diluted share, for the first nine months of 2005.
The Company's order backlog at September 30, 2006, was $4.94 million as compared with a $3.43 million backlog at June 30, 2006. The current backlog represents an increase of approximately $1.42 million from approximately $3.52 million as of September 30, 2005.
Robert P. Bruno, President & COO stated, "I am very pleased to announce that our third quarter machine orders increased by 124% versus the same period last year. In the year to date, machine orders have increased by 61% versus the same period last year.
One of the many highlights of the past quarter and for the year is the continuing strong sales for our M110EH laboratory machine. The number of M110EH machines shipped during the third quarter increased by 200% compared to the same period last year and shipments of this product, year to date, have nearly doubled compared to the same period last year.
Also, the number of M700 series pilot and production machines shipped during the quarter increased by 50% compared to the number of machines shipped during the same period last year and increased by 27%, year to date, compared to the same period last year."
Irwin Gruverman, Chairman & CEO commented, "We continued to experience a strong demand for our Microfluidizer® materials processing equipment during the third quarter. We believe that the current quarter's performance and the nine months revenue and profitability, combined with the backlog, are testimony to the effectiveness of our R&D reinvestment program in 2004 and 2005. Based on the backlog and expected shipments, we anticipate continued revenue growth in the fourth quarter versus the prior year's fourth quarter. We are committed to retaining our leadership in high pressure, high shear fluid processing and will continue the high level of investment in R&D and our efforts to ensure our future position in the industry."
Third Quarter 2006 Company Highlights
During the quarter, MFIC:
Shipped a high level of laboratory systems, including M110EH-30 lab machines
Booked more that $2.2 million in orders for large production equipment and production equipment interaction chambers.
Notice to Investors/Stockholders
MFIC will hold a conference call at 1:30 PM Eastern Time on Thursday, November 9, 2006 to discuss third quarter and nine months financial results. The domestic call in number is (800) 370 0898 and the Conference I.D. number is 8087245. Management's discussion will be followed by a question and answer period. For those who cannot listen to the live event, a replay of the call will be available on the Company's website: www.mficcorp.com.
MFIC CORPORATION
MFIC Corporation, through its Microfluidics subsidiary, provides patented and proprietary high performance Microfluidizer® materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
MFIC CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited - in thousands, except per share amounts)
For The Three For The Nine
Months Ended Months Ended
September 30, September 30,
----------------- ----------------
2006 2005 2006 2005
-------- ------- -------- -------
Revenues $ 3,553 $2,881 $10,614 $8,581
Cost of sales 1,558 1,527 4,806 4,283
-------- ------- -------- -------
Gross profit 1,995 1,354 5,808 4,298
-------- ------- -------- -------
Operating expenses:
Research and development 424 414 1,274 1,220
Selling 723 599 2,081 1,871
General and administrative 707 632 2,030 1,706
-------- ------- -------- -------
1,854 1,645 5,385 4,797
-------- ------- -------- -------
Income (loss) from operations 141 (291) 423 (499)
Interest expense (9) (13) (29) (45)
Interest income 10 7 31 18
-------- ------- -------- -------
Income (loss) before income tax
provision (benefit) 142 (297) 425 (526)
Income tax provision (benefit) 57 - 170 (77)
-------- ------- -------- -------
Net income (loss) $ 85 $ (297) $ 255 $ (449)
======== ======= ======== =======
Net income (loss) per common share:
Basic $ 0.01 $(0.03) $ 0.03 $(0.05)
Diluted $ 0.01 $(0.03) $ 0.02 $(0.05)
Weighted average number of common
and common equivalent shares
outstanding:
Basic 10,045 9,784 9,990 9,724
Diluted 10,561 9,784 10,517 9,724
Summary Consolidated Unaudited Balance Sheet Information
(Unaudited - in thousands, except per share data)
September 30, December 31,
2006 2005
--------------------------------------- --------------- --------------
Current Assets $7,004 $5,734
--------------------------------------- --------------- --------------
Current Liabilities $2,387 $1,461
--------------------------------------- --------------- --------------
Total Stockholders' Equity $4,880 $4,426
--------------------------------------- --------------- --------------
Equity Per Share $0.46 $0.45
--------------------------------------- --------------- --------------
Forward Looking Statement:
Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer® materials processing equipment or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect revenues and resulting net income for particular quarters in a manner that could cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.
Contact:
MFIC Corporation
Irwin Gruverman, CEO & Chairman
Robert P. Bruno, President & COO
Jack M. Swig, Investor Relations
617-969-5452
info@mfics.com
Well guys, I for one, always report the crooks to SEC (and other law enforcement).
Dear Sir or Madam:
Thank you for your recent e-mail to the group electronic mailbox of the Division of Enforcement at the United States Securities and Exchange Commission in Washington, D.C. We appreciate your taking the time to write to us. This automated response confirms that the Division of Enforcement has received your e-mail. You can rest assured that an attorney in the Office of Internet Enforcement will review your e-mail promptly.
We are always interested in hearing from members of the public, and you may be assured that the matter you have raised is being given careful consideration in view of the Commission's overall enforcement responsibilities under the federal securities laws. It is, however, the Commission's policy to conduct its inquiries on a confidential basis -- so this may be the only response that you receive. If your complaint is more in the nature of a consumer complaint (such as a dispute with your broker or a problem with your brokerage or retirement account), you should contact our Office of Investor Education and Assistance -- they may be able to help you. You may reach the Office of Investor Education and Assistance via telephone at (202) 551-6551or through the Web at HYPERLINK "http://www.sec.gov/complaint.shtml"www.sec.gov/complaint.shtml.
The Commission conducts its investigations on a confidential basis to preserve the integrity of its investigative process as well as to protect persons against whom unfounded charges may be made or against whom the Commission determines that enforcement action is not necessary or appropriate. Subject to the provisions of the Freedom of Information Act, we cannot disclose to you any information which we may gather and we cannot confirm to you the existence or non-existence of an investigation, unless made a matter of public record in proceedings brought before the Commission or in the courts.
If you are unsure where you should direct your inquiry or you want to learn more about how the SEC handles inquiries and complaints, please visit the SEC Complaint Center at HYPERLINK "http://www.sec.gov/complaint.shtml"www.sec.gov/complaint.shtml.
Should you have any additional information or questions pertaining to this matter, please feel free to communicate directly with us at HYPERLINK "mailto:enforcement@sec.gov"enforcement@sec.gov.
We appreciate your interest in the work of the Commission and its Division of Enforcement.
Very truly yours,
S/
John Reed Stark
Chief, Office of Internet Enforcement
United States Securities & Exchange Commission
I was quoting the last part of nanos statement "he,s out" and saying he will be "in" the big house when SEC gets thru with him :)
<- he's out!>
and when the SEC knocks on his door , he will be IN :)
Book Authors: Stem Cell Research Is Winning Mainstream Issue in 2006 Voting
Wednesday November 8, 2:22 pm ET
*** 2006 Election Vote Analysis ***
Impact Assessed in 25 Races, Ballot Measures by Authors of Forthcoming 'Stem Cell Research: Promise and Politics'
WASHINGTON, Nov. 8 /PRNewswire/ -- Stem cell research was a big winner in the 2006 mid-term election, according to an analysis of 25 races and ballot measures by Pam Solo and Gail Pressberg, authors of the soon-to-be-released "Stem Cell Research: Promise and Politics" (Praeger Publishers, 2006). The book will be shipped to bookstores nationwide on December 4, 2006. In a statement issued this morning, Solo and Pressberg said:
"Support for stem cell research played a prominent role in several key U.S. House, Senate and gubernatorial races, as well the closely watched constitutional amendment in Missouri. This is a health issue and people supported candidates of both parties who are either new to the issue or are 'tried and true,' such as Republican Congressman Mike Castle in Delaware. The power of politics from below and the role patients have played in keeping this issue at the forefront of the national agenda was reinforced again in this election.
In our overnight analysis of the outcome of 25 separate votes yesterday across America, we identified the following trends:
* Missouri was the bellwether state in terms of stem cell research, with
both a hotly contested U.S. Senate race and a constitutional amendment
up for grabs. The support of Missouri's middle America voters for stem
cell research was evident in the outcome: Democrat challenger Clare
McCaskill defeated incumbent Jim Talent, and Amendment 2 won on a 51-49
percent vote.
* At least four out of six Senate candidates who campaigned prominently in
support of stem cell research were victorious: Ben Cardin (Maryland),
Amy Klobuchar (Minnesota), Bob Menendez (New Jersey) and Sherrod Brown
(Ohio). Two other U.S. Senate races where stem cells figured in a major
way remain undecided as of this morning: Montana and Virginia. In both
cases, the Democrat challenger who actively campaigned in support of
stem cell research leads in the unofficial vote counts.
* Of the three gubernatorial races we identified, all three stem cell
research supporters won -- Jim Doyle in Wisconsin, Chet Culver in Iowa,
and Jan Granholm in Michigan. Of particular interest here is Wisconsin,
where Jim Doyle made stem cell research a centerpiece of his campaign.
He won re-election by a 53-45 margin.
* We also identified 15 House races where the issue of stem cell research
played a prominent role. In seven of those races -- Democrat Harry
Mitchell in AZ 05, Democrat Jerry McNerney in CA 11, Democrat Bruce
Braley in IA 01, Democrat Mike Arcuri in NY 24, Democrat Joe Sestak in
PA 07, and Democrat Steve Kagen in WI 08 -- the Democrat challenger
supporting stem cell research won. In four races, the Democrat who
campaigned in support of stem cell research lost - Tammy Duckworth in IL
06, Linda Stern in NJ 07, Dan Maffei in NY 25, and Eric Massa in NY 29.
Four races have not been officially called involving the following
candidates who focused on stem cell research -- NM 01 (Democrat Patricia
Madrid), OH 15 (Democrat Mary Jo Kilroy), PA 08 (Democrat Patrick
Murphy), and WA 08 (Democrat Darcy Burner).
What is the message here? There is a growing and grassroots demand for action at the federal level on stem cell research. This is a core lesson of the 2006 mid-term election: People want this research to go forward and politicians will be rewarded for taking a clear and unambiguous stand on the issue. This reflects the fact that stem cell research is not a 'right' or 'left' issue -- it is something that mainstream America wants to see happen."
As the forthcoming book "Stem Cell Research: Promise and Politics" notes: "Ever since President George W. Bush limited federal funding for stem cell research, the topic has been top of mind for many, including the organized patient population representing every major disease now afflicting approximately 100 million Americans ... How did scientific and medical research on something smaller than a period at the end of a sentence come to such prominence in American political life? ... Few areas of public policy have such far-reaching implications. This fact alone accounts for the remarkable level of information and sophistication by the broad general public."
In the book, Solo and Pressberg explain how the campaign for stem cell research was built in a bipartisan way across party lines. "Confounding the traditional polarized politics of the country previously dominated by anti- abortion and pro-choice politics, the politics of stem cell research may be redrawing the contours of public life. New political partnerships have been formed across party and ideological lines. Unusual and remarkable collaborations between scientists and patients have created a deeply informed constituency as advocates for the research. Rarely has a so-called cultural or value issue broken through the reflexive ideologies of left and right, conservative and liberal, as has the politics of stem cell research."
As Robert Goldstein, MD, PhD, MBA, Vice President and Chief Scientific Officer of the Juvenile Diabetes Research Foundation International, notes of the new book: "From its inception the debate about support for stem cell research has been a mixture of science and politics. Solo and Pressberg make an eloquent case that the discussion should not be left either to scientists or politicians alone but rather should include a vocal and informed public -- after all, the public has the largest stake in the outcome of this debate. They have defined a new role for public opinion -- active, intelligent, and outspoken-- and significantly raise the bar and define the potential role for public advocacy in future debates about other complex issues."
"'Stem Cell Research: Promise and Politics' makes it clear that the promise of stem cell treatment lies not in the halls of politics, but in the hearts of people," said Patti Davis, the author of "The Long Goodbye," a book about her father's struggle with Alzheimer's disease and the care that her mother, Nancy Reagan, provided. "No government can stand in the way of hope."
BUS 08:45 Unigene to Release Third Quarter 2006 Results and Host
Conference Call on November 10th
FAIRFIELD, N.J.--(BUSINESS WIRE)--November 08, 2006 Unigene Laboratories, Inc. (OTCBB: UGNE) will release financial results for the third quarter ended September 30, 2006, before the market opens on Friday, November 10th. The Company will also host a conference call that morning, at 9:00 AM EST to discuss its 2006 third quarter financial results.
Unigene invites all those interested in hearing management's
discussion of the third quarter results to join the call by dialing
877-407-0782 for participants in the United States and 201-689-8567
for international participants. A replay will be available for 45 days
after the call and can be accessed by dialing 877-660-6853 for
participants in the United States and 201-612-7415 for international
participants. When prompted, enter account # 286 and conference ID
#220249.
Got my fill at .135
Rushmore-you took the words right out of my mouth. It does,nt seem to matter a whit about all the promises they make in the PR,s. The ONE KEY figure everyone remembers is that big "$2.17" that Parkin threw out to us.
I send 6-8 of those scammer emails per day to either enforcement@sec.gov or spam@uce.gov. I would urge everyone to do the same.
Nancy Castro Pelosi:
New Speaker of the House Nancy Pelosi. Here are some things she recently said. Some of it sounds like stuff Fidel Castro would say:
Subject: Nancy Pelosi
Published: October 22, 2006
Nancy Pelosi condemed the new record highs of the stock market as "just
another example of Bush policies helping the rich get richer".
"First Bush cut taxes for the rich and the economy has rebounded with new
record low unemployment rates, which only means wealthy employers are
getting even wealthier at the expense of the underpaid working class".
She went on to say "Despite the billions of dollars being spent in Iraq
our economy is still strong and government tax revenues are at all time
highs. What this really means is that business is exploiting the war effort
and working Americans just to put money in their own pockets".
When questioned about recent stock market highs she r esponded "Only the
rich benefit from these record highs. Working Americans, welfare
recipients, the unemployed and minorities are not sharing in these obscene
record highs".
"There is no question these windfall profits and income created by the
Bush administration need to be taxed at 100% rate and those dollars
redistributed to the poor and working class".
"Profits from the stock market do not reward the hard work of our working
class who, buy their hard work, are responsible for generating these
corporate profits that create stock market profits for the rich. We in
congress will need to address this issue to either tax these profits or to
control the stock market to prevent this unearned income to flow to the
rich".
When asked about the fact that over 80% of all Americans have investments
in mutual funds, retirement funds, 401K's, and the stock market she replied
"That may be true, but probably only 5 % account for 90% of all these
investment dollars. That's just more "trickle down" economics claiming that
if a corporation is successful that everyone from the CEO to the floor
sweeper benefit from higher wages and job securuty which is ridiculous". How
much of this "trickle down" ever get to the unemployed and minorites in our
county? None, and that's the tragedy of these stock market highs."
"We democrats are going to address this issue after the election when we
take control of the congress. We will return to the 60% to 80% tax rates on
the rich and we will be able to take at least 30% of all currrent lower
Federal Income Tax taxpayers off the roles and increase government income
substantially. We need to work toward the goal of equalizing income in our
country and at the same time limiting the amount the rich can invest."
When asked how new these new tax dollars would be spent, she replied "We
need to raise the sta ndard of living of our poor, unemployed and minorities.
For example, we have an estimated 12 million illegal immigrents in our
country who need our help along with millions of unemployed minorities.
Stock market windfall profits taxes could go a long ways to guarantee these
people the standard of living they would like to have as Americans"
A Bush spoksman responded to this interview by saying "Mrs. Pelosi has set
a new standard for the spin business".
NanoViricides' CEO Comments on Decline in Company Share Price
Wednesday November 8, 7:30 am ET
WEST HAVEN, Conn.--(BUSINESS WIRE)--Eugene Seymour MD, MPH, CEO of NanoViricides, Inc. (Pink Sheets: NNVC - News) stated today that the Company knows of no reason for the recent drop in the price of the Company's shares.
Dr. Seymour said, "we are meeting our development goals faster then initially anticipated. During the past year we have achieved outstanding results, both in-vivo and in-vitro, on our anti-human influenza and anti-avian influenza drugs. Nothing has changed in the fundamentals of the company that should cause such a precipitous decline in share price
The Company has an aggressive development plan for the following year that takes into account the current world-wide concern over the possibility of an avian flu pandemic. Although stories about avian flu have virtually disappeared from the media, the possibility of a pandemic remains a serious concern for governments around the world. Information about avian influenza can be found at the official US government site, http://www.pandemicflu.gov
Dr Seymour has been invited to address the Third International Bird Flu Summit which will be held next week in Geneva, Switzerland. His talk, entitled The Use of a New Class of Drugs for the Treatment of Bird Flu: Nanotechnology-based Targeted Anti-Viral Therapeutics will be delivered to the attendees of the conference on November 15th. Information on the conference is available at http://www.bfsummit.com
About NanoViricides - http://www.nanoviricides.com
Contact:
NanoViricides, Inc.
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com
Whats with the US FDA? The Canadians gave ok for PIII of this cancer drug many months ago and FDA still sitting on their duffs while people are dying of head and neck cancer every day including a friend of mine!
By: se7en_strikes
05 Nov 2006, 08:00 PM EST
Msg. 5333 of 5333
Jump to msg. #
A very promising cancer therapy in late stage testing needs your help. Please write to the FDA (e-mail and mail address provided below):
A small US biotechnology company, CEL-SCI Corporation ( www. cel-sci. com ), has had a very promising cancer drug pending for a Phase III (final study) approval before the FDA for 22, yes you are reading correctly, 22 months. This same application was approved by the Canadian regulators in only 2 months. The Canadians and the FDA are supposed to use the same approval standards. What is the FDA doing? Please let the FDA know that this is not right. Cancer patients are dying while the FDA is delaying.
The Company has spent $90 million to develop this product called Multikine. The FDA has previously allowed studies with Multikine in head & neck cancer, prostate cancer, cervical dysplasia and HIV-infected patients, at a time when there was no safety data and no survival data. In these studies Multikine was shown to be very safe and in head & neck cancer it increased long-term survival by about 40%. Since the Company was allowed to study the product when there was no safety or survival data and the Canadian FDA has already approved the study, one has to wonder why the FDA is not moving ahead.
Let CEL-SCI run its Phase III clinical trial with Multikine and let the chips fall where they may!!!! If the drug turns out to be just half as good as it was in Phase II trials, it will be a breakthrough saving many lives.
The goal of Multikine is to make the first cancer treatment more successful. This means that Multikine would cure more patients with the first treatment. The Phase II clinical trial with Multikine showed about a 40% improvement in survival from Multikine. Anyone who has ever had cancer, or has a family member or friend with cancer, knows that recurrence of the cancer is bad, very bad. Multikine is designed to stop that recurrence.
Multikine cured 12% of head & neck cancer patients in 3 weeks, with no toxicity. Anyone who has ever seen the effects of radiation and chemotherapy can tell you how very amazing that is. On average Multikine killed 50% of the tumor cells in just a few weeks. It appears to enhance the killing of cancer cells with radiation and chemotherapy.
CEL-SCI's results were published in leading peer-reviewed journals. The Canadians approved the Phase III study in 2 months. Why is the drug not allowed to move forward with excellent safety and promising efficacy data when it was allowed to move forward when there was no data? Is the drug, now that there is promising data, a threat to someone?
Please write to the FDA and let them know that you find this delay unacceptable. A safe cancer drug with promise should not be held up for politics. Too many people are dying of cancer every day. FDA finally has a new Commissioner, Dr. Andrew von Eschenbach. He probably does not even know about this travesty. Let him know and ask him to look into this. He can make a difference. Please contact him today.
Please write to the Commissioner as a concerned citizen and ask him to move CEL-SCI?s application along so that Multikine gets a chance to prove itself in Phase III studies. Patients are dying and there is a drug that looks like it could help a good number of them.
andrew. voneschenbach@fda. hhs. gov
or
Office of the Commissioner, FDA
Parklawn Building HF-1
Room 1471
5600 Fishers Lane
Rockville, MD 20857
Please forward this letter to as many of your friends as possible and post it on chat board or blogs.
Thank you!!!!!!
Why has USFDA not acted?
By: se7en_strikes
05 Nov 2006, 08:00 PM EST
Msg. 5333 of 5333
Jump to msg. #
A very promising cancer therapy in late stage testing needs your help. Please write to the FDA (e-mail and mail address provided below):
A small US biotechnology company, CEL-SCI Corporation ( www. cel-sci. com ), has had a very promising cancer drug pending for a Phase III (final study) approval before the FDA for 22, yes you are reading correctly, 22 months. This same application was approved by the Canadian regulators in only 2 months. The Canadians and the FDA are supposed to use the same approval standards. What is the FDA doing? Please let the FDA know that this is not right. Cancer patients are dying while the FDA is delaying.
The Company has spent $90 million to develop this product called Multikine. The FDA has previously allowed studies with Multikine in head & neck cancer, prostate cancer, cervical dysplasia and HIV-infected patients, at a time when there was no safety data and no survival data. In these studies Multikine was shown to be very safe and in head & neck cancer it increased long-term survival by about 40%. Since the Company was allowed to study the product when there was no safety or survival data and the Canadian FDA has already approved the study, one has to wonder why the FDA is not moving ahead.
Let CEL-SCI run its Phase III clinical trial with Multikine and let the chips fall where they may!!!! If the drug turns out to be just half as good as it was in Phase II trials, it will be a breakthrough saving many lives.
The goal of Multikine is to make the first cancer treatment more successful. This means that Multikine would cure more patients with the first treatment. The Phase II clinical trial with Multikine showed about a 40% improvement in survival from Multikine. Anyone who has ever had cancer, or has a family member or friend with cancer, knows that recurrence of the cancer is bad, very bad. Multikine is designed to stop that recurrence.
Multikine cured 12% of head & neck cancer patients in 3 weeks, with no toxicity. Anyone who has ever seen the effects of radiation and chemotherapy can tell you how very amazing that is. On average Multikine killed 50% of the tumor cells in just a few weeks. It appears to enhance the killing of cancer cells with radiation and chemotherapy.
CEL-SCI's results were published in leading peer-reviewed journals. The Canadians approved the Phase III study in 2 months. Why is the drug not allowed to move forward with excellent safety and promising efficacy data when it was allowed to move forward when there was no data? Is the drug, now that there is promising data, a threat to someone?
Please write to the FDA and let them know that you find this delay unacceptable. A safe cancer drug with promise should not be held up for politics. Too many people are dying of cancer every day. FDA finally has a new Commissioner, Dr. Andrew von Eschenbach. He probably does not even know about this travesty. Let him know and ask him to look into this. He can make a difference. Please contact him today.
Please write to the Commissioner as a concerned citizen and ask him to move CEL-SCI?s application along so that Multikine gets a chance to prove itself in Phase III studies. Patients are dying and there is a drug that looks like it could help a good number of them.
andrew. voneschenbach@fda. hhs. gov
or
Office of the Commissioner, FDA
Parklawn Building HF-1
Room 1471
5600 Fishers Lane
Rockville, MD 20857
Please forward this letter to as many of your friends as possible and post it on chat board or blogs.
Thank you!!!!!!
Many CVM investors are not happy with the long wait and blame Cel-Sci but why did the Canadians ok PIII many months ago and USFDA has been sitting on it?
By: se7en_strikes
05 Nov 2006, 08:00 PM EST
Msg. 5333 of 5333
Jump to msg. #
A very promising cancer therapy in late stage testing needs your help. Please write to the FDA (e-mail and mail address provided below):
A small US biotechnology company, CEL-SCI Corporation ( www. cel-sci. com ), has had a very promising cancer drug pending for a Phase III (final study) approval before the FDA for 22, yes you are reading correctly, 22 months. This same application was approved by the Canadian regulators in only 2 months. The Canadians and the FDA are supposed to use the same approval standards. What is the FDA doing? Please let the FDA know that this is not right. Cancer patients are dying while the FDA is delaying.
The Company has spent $90 million to develop this product called Multikine. The FDA has previously allowed studies with Multikine in head & neck cancer, prostate cancer, cervical dysplasia and HIV-infected patients, at a time when there was no safety data and no survival data. In these studies Multikine was shown to be very safe and in head & neck cancer it increased long-term survival by about 40%. Since the Company was allowed to study the product when there was no safety or survival data and the Canadian FDA has already approved the study, one has to wonder why the FDA is not moving ahead.
Let CEL-SCI run its Phase III clinical trial with Multikine and let the chips fall where they may!!!! If the drug turns out to be just half as good as it was in Phase II trials, it will be a breakthrough saving many lives.
The goal of Multikine is to make the first cancer treatment more successful. This means that Multikine would cure more patients with the first treatment. The Phase II clinical trial with Multikine showed about a 40% improvement in survival from Multikine. Anyone who has ever had cancer, or has a family member or friend with cancer, knows that recurrence of the cancer is bad, very bad. Multikine is designed to stop that recurrence.
Multikine cured 12% of head & neck cancer patients in 3 weeks, with no toxicity. Anyone who has ever seen the effects of radiation and chemotherapy can tell you how very amazing that is. On average Multikine killed 50% of the tumor cells in just a few weeks. It appears to enhance the killing of cancer cells with radiation and chemotherapy.
CEL-SCI's results were published in leading peer-reviewed journals. The Canadians approved the Phase III study in 2 months. Why is the drug not allowed to move forward with excellent safety and promising efficacy data when it was allowed to move forward when there was no data? Is the drug, now that there is promising data, a threat to someone?
Please write to the FDA and let them know that you find this delay unacceptable. A safe cancer drug with promise should not be held up for politics. Too many people are dying of cancer every day. FDA finally has a new Commissioner, Dr. Andrew von Eschenbach. He probably does not even know about this travesty. Let him know and ask him to look into this. He can make a difference. Please contact him today.
Please write to the Commissioner as a concerned citizen and ask him to move CEL-SCI?s application along so that Multikine gets a chance to prove itself in Phase III studies. Patients are dying and there is a drug that looks like it could help a good number of them.
andrew. voneschenbach@fda. hhs. gov
or
Office of the Commissioner, FDA
Parklawn Building HF-1
Room 1471
5600 Fishers Lane
Rockville, MD 20857
Please forward this letter to as many of your friends as possible and post it on chat board or blogs.
Thank you!!!!!!
For those who have friends/family with head and neck cancer.
By: se7en_strikes
05 Nov 2006, 08:00 PM EST
Msg. 5333 of 5333
Jump to msg. #
A very promising cancer therapy in late stage testing needs your help. Please write to the FDA (e-mail and mail address provided below):
A small US biotechnology company, CEL-SCI Corporation ( www. cel-sci. com ), has had a very promising cancer drug pending for a Phase III (final study) approval before the FDA for 22, yes you are reading correctly, 22 months. This same application was approved by the Canadian regulators in only 2 months. The Canadians and the FDA are supposed to use the same approval standards. What is the FDA doing? Please let the FDA know that this is not right. Cancer patients are dying while the FDA is delaying.
The Company has spent $90 million to develop this product called Multikine. The FDA has previously allowed studies with Multikine in head & neck cancer, prostate cancer, cervical dysplasia and HIV-infected patients, at a time when there was no safety data and no survival data. In these studies Multikine was shown to be very safe and in head & neck cancer it increased long-term survival by about 40%. Since the Company was allowed to study the product when there was no safety or survival data and the Canadian FDA has already approved the study, one has to wonder why the FDA is not moving ahead.
Let CEL-SCI run its Phase III clinical trial with Multikine and let the chips fall where they may!!!! If the drug turns out to be just half as good as it was in Phase II trials, it will be a breakthrough saving many lives.
The goal of Multikine is to make the first cancer treatment more successful. This means that Multikine would cure more patients with the first treatment. The Phase II clinical trial with Multikine showed about a 40% improvement in survival from Multikine. Anyone who has ever had cancer, or has a family member or friend with cancer, knows that recurrence of the cancer is bad, very bad. Multikine is designed to stop that recurrence.
Multikine cured 12% of head & neck cancer patients in 3 weeks, with no toxicity. Anyone who has ever seen the effects of radiation and chemotherapy can tell you how very amazing that is. On average Multikine killed 50% of the tumor cells in just a few weeks. It appears to enhance the killing of cancer cells with radiation and chemotherapy.
CEL-SCI's results were published in leading peer-reviewed journals. The Canadians approved the Phase III study in 2 months. Why is the drug not allowed to move forward with excellent safety and promising efficacy data when it was allowed to move forward when there was no data? Is the drug, now that there is promising data, a threat to someone?
Please write to the FDA and let them know that you find this delay unacceptable. A safe cancer drug with promise should not be held up for politics. Too many people are dying of cancer every day. FDA finally has a new Commissioner, Dr. Andrew von Eschenbach. He probably does not even know about this travesty. Let him know and ask him to look into this. He can make a difference. Please contact him today.
Please write to the Commissioner as a concerned citizen and ask him to move CEL-SCI?s application along so that Multikine gets a chance to prove itself in Phase III studies. Patients are dying and there is a drug that looks like it could help a good number of them.
andrew. voneschenbach@fda. hhs. gov
or
Office of the Commissioner, FDA
Parklawn Building HF-1
Room 1471
5600 Fishers Lane
Rockville, MD 20857
Please forward this letter to as many of your friends as possible and post it on chat board or blogs.
Thank you!!!!!!
Good post. I had the feeling all along this was causing the delay in AF,s and I still do.
DrFeelgood, and this from the IHub "Birdflu Stock play" board recently posted:
just pFree Zone | User's Groups | BIRD FLU STOCK PLAYS (BIRDFLU)
Public Reply | Private Reply | Keep | Last Read Replies (1) | Next 10 | Previous | Next
Posted by: sludgehound
In reply to: None Date:10/30/2006 10:43:21 PM
Post #of 1382
Super strain bird flu in China
H5N1 strain could start wave of bird flu outbreaks By Tan Ee Lyn
Mon Oct 30, 4:10 PM ET
Scientists in Hong Kong and the United States have detected a new strain of H5N1 bird flu virus in China and warned it might have started another wave of outbreaks in poultry in Southeast Asia and move deeper into Eurasia.
The strain, called the "Fujian-like virus" because it was first isolated in China's southern Fujian province in March 2005, has increasingly been detected since October 2005 in poultry in six provinces in China, displacing other H5N1 strains.
The strain might also have become resistant to vaccines, which China began using on a large scale from September 2005 to protect poultry from H5N1, said the scientists.
The researchers are from the University of Hong Kong, including virologists Guan Yi and Malik Peiris, and Rob Webster of St Jude Children's Research Hospital in the United States.
"The predominance of this Fujian-like virus appears to be responsible for the increased prevalence of H5N1 in poultry since October 2005 and recent human infection cases in China," they said in an article published in the U.S.-based Proceedings of the National Academy of Sciences (www.pnas.org).
"It has already caused poultry outbreaks in Laos, Malaysia and Thailand, and human disease in Thailand. It is likely that this variant has already initiated a third wave of transmission throughout Southeast Asia and may spread further in Eurasia."
The first wave of H5N1 outbreaks occurred in late 2003 and 2004 in many parts of Asia. The second wave started in China's Qinghai Lake in May 2005 and that strain has since been found in parts of Europe, Africa and the Middle East.
The virus has killed more than 150 people since late 2003 and remains largely a disease among birds. But experts fear it could trigger a flu pandemic and kill millions of people if it mutates into a strain that can pass from human to human.
SUPER STRAIN
The researchers collected 53,220 fecal samples from chickens, geese and ducks in poultry markets in six Chinese provinces between July 2005 and June 2006. Of these, 1,294 tested positive for H5N1.
But genetic sequencing of viruses collected from October 2005 onwards showed the Fujian strain was clearly becoming predominant over other H5N1 strains. Between April and June this year, 103 out of 108 H5N1-positive samples were of the Fujian type.
"That's pretty conclusive proof that this new variant is predominant," said Gavin Smith, one of the researchers in the Hong Kong team.
To test how well vaccinated poultry could stand up to various strains of H5N1, the researchers collected 1,113 blood samples from chickens from November 2005 to April 2006.
Only 180 samples, or 16 percent, tested positive for H5N1 antibodies. They were exposed to 3 strains of H5N1 -- namely the Yunnan, Guiyang and Fujian-like strains.
The antibodies managed to neutralize the Yunnan and Guiyang strains, but had little or no effect on the Fujian virus.
"The market poultry, many of them don't have antibodies against H5 virus and those that do are not well protected against the Fujian virus, which is why we think the Fujian-like virus has been able to grow because other (strains) have been suppressed," Smith told Reuters in an interview.
"What happens with vaccines is that you basically introduce something that kills off most of the viruses, but there are always going to be some viruses that can escape from it."
trendy, perhaps we should send his posts to the SEC and let them decide?
There was a post at one time showing micromatty had a reward posted for his head(lying) from another company.